# US 2024/0199618 A1 · NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199618 A1
- Document ID: US20240199618A1
- Status: Published application
- Kind: A1
- Application number: 18/235,976
- Filed: 2023-08-21
- Published: 2024-06-20
- Earliest claimed: 2013-03-29
- Assignees: Ogeda SA
- Applicants: Ogeda SA
- Inventors: Hamid Hoveyda; Guillaume Dutheuil; Graeme Fraser
- Web page: https://patentgrep.com/patent/US20240199618A1

## CPC

- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.

## Claims

### Claim 1

A method of preventing and/or treating moderate and severe hot flashes in a patient, comprising administering to a patient in need thereof for at least four weeks a pharmaceutically effective amount of the following compound:
wherein the frequency of hot flashes in the patient after at least four weeks of treatment is reduced compared to the frequency of hot flashes in the patient before at least four weeks of treatment.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the moderate and severe hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the moderate and severe hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the moderate and severe hot flashes are selected from the group consisting of therapy-induced hot flashes in breast cancer, therapy-induced hot flashes in uterine cancer, and therapy-induced hot flashes in prostate cancer.

### Claim 5

A method for preventing and/or treating moderate and severe hot flashes in a patient, comprising administering to a patient in need thereof for at least four weeks a pharmaceutically effective amount of the following compound:
wherein the severity of hot flashes in the patient after at least four weeks of treatment is reduced compared to the severity of hot flashes in the patient before at least four weeks of treatment.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the moderate and severe hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the moderate and severe hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the moderate and severe hot flashes are selected from the group consisting of therapy-induced hot flashes in breast cancer, therapy-induced hot flashes in uterine cancer, and therapy-induced hot flashes in prostate cancer.
